13,100 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,100 shares of the company’s stock, valued at approximately $631,000.

A number of other institutional investors also recently bought and sold shares of KNSA. Amundi acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kiniksa Pharmaceuticals International by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after acquiring an additional 1,002 shares during the period. Millennium Management LLC increased its position in Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares during the period. Creative Planning purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $358,000. Finally, Quantbot Technologies LP purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $43,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

More Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Multiple analysts raised price targets: Goldman Sachs increased its target to $90 and initiated a “buy” rating; JPMorgan raised its target to $107 with an “overweight” rating; Canaccord Genuity lifted its target to $98 and maintained a “buy” rating; Wedbush raised its target to $99 with an “outperform” rating; and Citi increased its target to $100 with a “buy” rating. The broad upward revisions signal growing confidence in KNSA’s commercial outlook and pipeline. Benzinga analyst price-target reports
• Positive Sentiment: Higher earnings estimates could support additional gains. Zacks reported that analysts are raising estimates for Kiniksa, a trend that often reflects improving expectations for future revenue and profitability. Zacks earnings estimates article
• Positive Sentiment: Raised 2026 guidance and pipeline progress drove the initial rally. Coverage highlighted Kiniksa’s stronger revenue outlook and advancement of its development pipeline, reinforcing expectations for continued growth. Yahoo Finance guidance and pipeline article
• Positive Sentiment: Quarterly results exceeded revenue expectations. Kiniksa reported $243.6 million in revenue versus the $226.5 million consensus estimate, while adjusted EPS of $0.30 matched expectations. Kalkine Media Kiniksa earnings announcement
• Negative Sentiment: Valuation is a risk after the sharp advance. One analysis suggested KNSA could be approximately 16% overvalued even after the guidance increase, potentially limiting upside or prompting profit-taking if growth expectations moderate. Yahoo Finance KNSA valuation article

Analyst Upgrades and Downgrades

KNSA has been the topic of several analyst reports. Wedbush lifted their target price on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research note on Wednesday. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Canaccord Genuity Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Citigroup boosted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $87.38.

Kiniksa Pharmaceuticals International Stock Down 3.4%

Shares of NASDAQ:KNSA opened at $78.20 on Friday. Kiniksa Pharmaceuticals International, plc has a 52 week low of $29.90 and a 52 week high of $82.94. The company has a 50-day moving average price of $58.62 and a 200 day moving average price of $50.96. The company has a market cap of $6.02 billion, a P/E ratio of 80.62 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.30. The company had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. Analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.39 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.